We appreciate the commentary on our article by Foster and Beard, both employees of Ipsen. We would like to take the opportunity to address several points raised in their commentary.
examined NAb prevalence in patients treated with BoNT for spasticity. This indication, as discussed in our review [1] , appears to have a very low rate of NAbs formation and, therefore, is not suitable for addressing immunogenicity. Likewise, the review by Lacroix-Desmazes et al. [6] is not appropriate for citation as the investigators excluded data from studies on patients with SNR.
In our review we noted that some patients desire shorter injection cycles, based on a survey which found that 45% of patients expressed preference for a treatment cycle of less than 10 weeks [11] . Although this view is frequently expressed by patients treated with BoNT, we certainly do not endorse or advocate for "booster" injections, which in the past have been associated with high frequency of immunoresistance [1] . Most studies examining the effects and safety of shorter inter-dose intervals used incobotulinumtoxinA [12] [13] [14] , but more comparative data are needed before concluding that one product or another is associated with less immunogenicity or longer duration of action [15] .
Many of the points raised in the commentary by Foster and Beard are echoed in our review [1] . Immunoresistance is a rare phenomenon and accounts for a small minority of patients found to be unresponsive to BoNT. The relationship between NAbs and SNR is unclear; however, it cannot be fully discounted. Comparison of NAb formation rates between formulations or between studies is challenging due to a variety of factors, including different patient populations and study methodologies, and varied assays used to measure clinical response and NAbs. We agree that clinical tests, such as the unilateral brow injection, while predictive of future unresponsiveness, do not necessarily reflect immunogenicity. Finally, we agree with the conclusion by the authors of the commentary that "BoNT therapy is a highly effective and important therapy for the treatment of a variety of neurological and non-neurological conditions." 
